Considerations when prescribing REXULTI
In this 2-minute video, Dr Ilan Melnick reviews which patients may be suitable for REXULTI, when it can be prescribed and what you can expect from the safety profile.
-
Body
PBS Information: Authority required (STREAMLINED). Code: 4246 for schizophrenia. This product is not listed on the PBS for the treatment of agitation associated with Alzheimer’s dementia.
-
Body
Please review Approved Product Information before prescribing.
Product Information is available by calling Lundbeck on 1300 721 277 or by clicking:REXULTI® is a registered trademark of H. Lundbeck A/S. REXULTI® is co-commercialised by Lundbeck Australia and Otsuka Australia Pharmaceutical Pty Limited.
Related
Contributor
Dr Ilan Melnick